Clinical Trials Browser

Anatomic Stage II Breast Cancer AJCC v8

Breast Neoplasms

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Advanced Breast Cancer

Breast Neoplasms

Breast Neoplasm Female

Breast Neoplasms

Triple Negative Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Resectable HER2-positive Breast Cancer

Breast Neoplasms

Anatomic Stage I Breast Cancer AJCC v8

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Anatomic Stage I Breast Cancer AJCC v8

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Advanced Breast Cancer

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

Breast Neoplasms

Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

Breast Neoplasms, Depression

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

HER2-positive Breast Cancer

Breast Neoplasms

Breast Neoplasms, Pain, Postoperative

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Neoplasm, Residual

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Breast Neoplasms

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

Clinical Trials

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

OPERA-02

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

DEBRA

TAILOR RT

Adjuvant WIDER

EvoPAR-BR01

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)

CAMBRIA-1

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

TroFuse-011

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

ELAINEIII

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

BRIA-ABC

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

ADELA

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

INAVO123

OFSET

MK-2870-010

HEAL-ABC

ReDiscover-2

INAVO122

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

ELEGANT

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

LOLIPOP

BCTOP-T-M01

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

FLAMINGO-01

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

TB06

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

NoLEEta

OPERA-01

CAPItello-292

Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment

FourLight-3